{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:23:46Z","timestamp":1773275026398,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,12,8]],"date-time":"2009-12-08T00:00:00Z","timestamp":1260230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>We examined clinical outcomes, patient characteristics and trends over time of non\u2010medically supervised treatment interruptions (TIs) from a free\u2010of\u2010charge antiretroviral therapy (ART) programme in British Columbia (BC), Canada.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from ART\u2010na\u00efve individuals \u226518 years old who initiated triple combination highly active antiretroviral therapy (HAART) between January 2000 and June 2006 were analysed. Participants having \u22653 month gap in HAART coverage were defined as having a TI. Cox proportional hazards modelling was used to examine factors associated with TIs and to examine factors associated with resumption of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1707 participants were study eligible and 643 (37.7%) experienced TIs. TIs within 1 year of ART initiation decreased from 29% of individuals in 2000 to 19% in 2006 (<jats:italic>P<\/jats:italic>&lt;0.001). TIs were independently associated with a history of injection drug use (IDU) (<jats:italic>P<\/jats:italic>=0.02), higher baseline CD4 cell counts (<jats:italic>P<\/jats:italic>&lt;0.001), hepatitis C co\u2010infection (<jats:italic>P<\/jats:italic>&lt;0.001) and the use of nelfinavir (NFV) (<jats:italic>P<\/jats:italic>=0.04) or zidovudine (ZDV)\/lamivudine (3TC) (<jats:italic>P<\/jats:italic>=0.009) in the primary HAART regimen. Male gender (<jats:italic>P<\/jats:italic>&lt;0.001), older age (<jats:italic>P<\/jats:italic>&lt;0.001), AIDS at baseline (<jats:italic>P<\/jats:italic>=0.008) and having a physician who had prescribed HAART to fewer patients (<jats:italic>P<\/jats:italic>=0.03) were protective against TIs. Four hundred and eighty\u2010eight (71.9%) participants eventually restarted ART with male patients and those who developed an AIDS\u2010defining illness prior to their TI more likely to restart therapy. Higher CD4 cell counts at the time of TI and unknown hepatitis C status were associated with a reduced likelihood of restarting ART.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Treatment interruptions were associated with younger, less ill, female and IDU participants. Most participants with interruptions eventually restarted therapy. Interruptions occurred less frequently in recent years.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2009.00779.x","type":"journal-article","created":{"date-parts":[[2009,12,8]],"date-time":"2009-12-08T13:36:37Z","timestamp":1260279397000},"page":"299-307","source":"Crossref","is-referenced-by-count":29,"title":["Non\u2010medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme"],"prefix":"10.1111","volume":"11","author":[{"given":"DM","family":"Moore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Yip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Genebat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VD","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JSG","family":"Montaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RS","family":"Hogg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,4,11]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.6.450"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60693-5"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69162-9"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/422601"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32802e6bfa"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31815ace7e"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.6.547"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181648dfd"},{"key":"e_1_2_6_10_2","first-page":"743","article-title":"Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen","volume":"21","author":"Mocroft A","year":"2005","journal-title":"increased incidence of stopping due to toxicity or patient\/physician choice in patients with hepatitis C coinfection"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200312010-00008"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000138160.91568.19"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540120412331319778"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2006.00355.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/154510970200100304"},{"key":"e_1_2_6_16_2","first-page":"555","article-title":"Antiretroviral treatment of adult HIV infection","volume":"300","author":"Hammer SM","year":"2008","journal-title":"2008 recommendations of the International AIDS Society-USA panel"},{"key":"e_1_2_6_17_2","unstructured":"British Columbia Centre for Excellence in HIV\/AIDS.Therapeutic guidelines for the treatment of HIV\/AIDS and related conditions. Available athttp:\/\/www.cfenet.ubc.ca\/webuploads\/files\/06_2826_TherapeuticGuidelines_3.pdf(accessed 23 July 2008)."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2007.01975.x"},{"key":"e_1_2_6_19_2","first-page":"848","article-title":"Individual variability in barriers affecting people's decision to take HAART","volume":"20","author":"Alfonso V","year":"2006","journal-title":"a qualitative study identifying barriers to being on HAART"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31802c2f51"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jurban\/jti076"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-3-14"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69118-6"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062360"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2009.00779.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2009.00779.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T07:34:52Z","timestamp":1698651292000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2009.00779.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,11]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1111\/j.1468-1293.2009.00779.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00779.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,11]]}}}